Construction method of recombinant chicken bursal disease virus VP2 gene expression system
By constructing a CHO expression system for recombinant chicken bursal virus VP2 gene, the problems of unstable expression and broad-spectrum protection of VP2 protein in the prior art are solved, efficient expression and stability are achieved, suitable for industrial production, and the vaccine is improved Immunogenicity.
Patent Information
- Application Number
- CN202411011918.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
The existing expression system is difficult to achieve efficient expression of the infectious bursal virus VP2 protein of chickens. As the virus strain mutates, commercial vaccines cannot provide broad-spectrum protection, and the expression effects are uneven, making it difficult to be suitable for industrial production.
The CHO expression system of the recombinant chicken bursal virus VP2 gene was constructed. By connecting the recombinant VP2 gene to the signal peptide and expressing it in CHO cells, the plasmid construction and expression were performed using the pEE12.4 vector to achieve efficient and stable protein expression.
It achieves efficient expression and stability of VP2 protein, provides effective protection against different strains, and is suitable for industrial production, lays the foundation for the development of chicken bursal subunit vaccine, and improves the immunogenicity of the vaccine.
Smart Images

Figure CN118931962A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of veterinary biological products, specifically relating to a method for constructing an expression system for the recombinant chicken infectious bursal virus VP2 gene. Background Technology
[0002] Infectious bursal disease (IBD) is an acute, highly contagious disease caused by the infectious bursal disease virus (IBDV). IBD primarily infects chicks aged 3-6 weeks, exhibiting high infectivity, a short incubation period, and a high mortality rate, seriously threatening the development of the poultry industry. Currently, prevention and control of this disease mainly rely on vaccines. Given the advantages of genetically engineered vaccines—good safety profile and lack of interference from maternal antibodies—genetically engineered IBDV vaccines are gradually becoming a research hotspot. The VP2 protein is the main structural protein of IBDV, accounting for 51% of the total IBDV protein, and is also the virus's main protective antigen, exhibiting serotype specificity. Therefore, using the VP2 protein to prepare vaccines can effectively prevent and control IBDV.
[0003] Current research has explored the expression of VP2 protein using yeast, prokaryotic, and baculovirus expression systems. Animal experiments have demonstrated that these expressed VP2 proteins possess certain immunogenicity and can serve as candidates for infectious bursal disease (IBDV) subunit vaccines. However, with the continuous mutation of chicken IBDV strains, commercially available IBDV vaccines no longer provide broader-spectrum protection. Furthermore, the expression efficiency of VP2 protein varies due to the limitations of the expression system, and existing conventional expression systems and methods cannot achieve efficient VP2 protein expression, hindering industrial-scale production. Therefore, there is an urgent need to construct an expression system capable of achieving efficient expression and suitable for industrial production. Summary of the Invention
[0004] The purpose of this invention is to provide a method for constructing an expression system for the recombinant chicken infectious bursal virus VP2 gene.
[0005] Another objective of this invention is to provide an expression system for the recombinant chicken infectious bursal virus VP2 gene.
[0006] A recombinant chicken infectious bursal virus VP2 gene expression system, the expression system comprising an expression cassette consisting of a recombinant chicken infectious bursal virus VP2 gene, a signal peptide, and a vector; the nucleotide sequence of the recombinant chicken infectious bursal virus VP2 gene is shown in SEQ ID NO. 1.
[0007] Furthermore, the recombinant chicken infectious bursal virus VP2 gene expression system was constructed using mammalian cell CHO.
[0008] Furthermore, the signal peptide is any one of Human IL-2, Human OSM, and Mouse Igκ.
[0009] Furthermore, the vector is a pEE12.4 vector, which is ligated after double digestion with HindIII and EcoRI.
[0010] Furthermore, the construction method of the recombinant chicken infectious bursal virus VP2 gene expression system includes:
[0011] 1) Link the N-terminus of the recombinant chicken infectious bursal virus VP2 gene sequence to a signal peptide;
[0012] 2) The pEE12.4 vector was double-digested with HindIII and EcoRI and then ligated with the product in 1).
[0013] 3) The ligation product from 2) was transformed into DH5α and the plasmid was extracted;
[0014] 4) Use CHO cells to express the plasmid from 3).
[0015] The method for constructing the expression system of the recombinant chicken infectious bursal virus VP2 gene is applied in the preparation of chicken infectious bursal virus vaccine.
[0016] Compared with the prior art, the present invention has the following advantages:
[0017] This invention modifies the extracted chicken infectious bursal virus VP2 genome sequence, adds a signal peptide sequence to the modified sequence, and constructs a CHO expression system for the recombinant chicken infectious bursal virus VP2 gene. The system has stable expression performance, high protein content, and is suitable for large-scale production, laying a good foundation for the development of chicken infectious bursal subunit vaccines.
[0018] The present invention utilizes proteins expressed in CHO mammalian cells, which, after translational processing, have a structure and biological characteristics that are closer to those of natural proteins. Therefore, the vaccines prepared from these proteins have stronger immunogenicity.
[0019] The chicken infectious bursal virus vaccine prepared by this invention has a certain protective effect against different strains of chicken infectious bursal virus. Attached Figure Description
[0020] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:
[0021] Figure 1The image shows the PCR identification of the chicken infectious bursa of Fabricius VP2 gene, where M is the DL5000 DNA Marker and 1 is the unoptimized IBDV VP2 gene fragment.
[0022] Figure 2 The image shows the SDS-PAGE results of the CHO-S supernatant of the chicken bursal VP2 gene. In the image, 1-2 are BSA at 0.1 mg / mL and 0.2 mg / mL, respectively. 3-6 are the expression supernatants after CHO-S transfection guided by the SP1, SP2, SP3 and SP4 signal peptide sequences, respectively. 7 is the negative control.
[0023] Figure 3 The image shows the Western blot results of the CHO-S supernatant of the chicken bursa of Fabricius VP2 gene. Figures 1-4 show the expression results of the culture supernatant after transfection with the SP1-IBDV VP2, SP2-IBDV VP2, SP3-IBDV VP2, and SP4-IBDV VP2 sequences, respectively. Detailed Implementation
[0024] The following detailed descriptions are exemplary and intended to provide further explanation of the present invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present invention without departing from the spirit and scope thereof, but all such modifications and substitutions fall within the protection scope of the present invention.
[0025] Unless otherwise specified, the experimental methods used in the following experimental examples are all conventional methods.
[0026] Example 1: Construction method of recombinant chicken bursal disease VP2 gene expression system
[0027] 1. Optimization of recombinant sequences and construction of expression cassettes
[0028] The pathogenic materials used in this study were obtained from an egg-laying chicken farm in Baoding City, Hebei Province. Chickens suspected of exhibiting characteristics of infectious bursal disease (IBD) were selected as pathogenic materials. The genome of the pathogenic materials was extracted and isolated, and the VP2 ORF sequence was verified by PCR using primers VP2-F: atgacaaacctgcaagat and VP2-R: ccttagggcccgaattat. The PCR product was ligated into the pMD18T vector and sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing. The sequencing results showed a high degree of similarity to the VP2 genome sequence of the infectious bursal disease virus (Gene Bank No: MZ736578.1).
[0029] ① Optimization of recombinant sequences
[0030] The obtained IBDV VP2 gene sequence was modified and optimized according to the codons preferred by CHO cells. The modified gene sequence is shown in SEQ NO 1.
[0031] ② Construction of the expression box
[0032] The optimized sequence was ligated to the N-terminus of different signal peptide sequences in Table 1, and HindIII and EcoRI restriction sites were added. After double digestion, the sequence was inserted into the pEE12.4 vector to obtain the pEE12.4-SP-IBDV VP2 plasmid, which contains four expression cassettes.
[0033] Table 1. Names and sequences of selected signal peptides
[0034]
[0035] 2. Transient expression of IBDV VP2
[0036] ①CHO-S cell preparation: CHO-S cells should have a viability of over 95%, a diameter of 14-15 mm, and be uniform in size and translucent. The cells should be prepared at a rate of 2*10⁻⁶ cells per cell line the day before transfection. 6 passaged per mL.
[0037] ② Cell transfection: The cell density reaches 3-4*10⁻⁴ the next day. 6 The survival rate was above 95%. Transfection was performed at 1 μg / mL, with 5% feeding every 2 days. After 10 days, the culture supernatant was collected, and the protein expression in the culture supernatant was detected by SDS-PAGE and Western blot.
[0038] 3. Stable expression of IBDV VP2
[0039] ① Screening to obtain a stable cell pool: Under 280V voltage conditions, CHO-K1 suspension cells were electrotransfected with the plasmid that expressed the highest transient transfection level. After electrotransfection, the cells were screened with L-methionine sulfoxide imide (L-MSX) for two rounds of drug pressure. A cell pool expressing IBDV VP2 protein was obtained. The cell pool was cultured for more than 15 generations. The cell line that stably expressed the protein was the stable transfected cell line. A total of 3 cell lines were screened and named Clone1, Clone2 and Clone3.
[0040] ② Verification of stable clonal expression: Three stable cell lines were cultured in shake flasks using a fed-batch method, i.e., at a ratio of 5 x 10⁻⁶ cells / mL. 5 Inoculate with stable cell lines, then culture for 12 days, feeding every 2 days, and collect the culture supernatant on the 12th day.
[0041] 4. Verification of Expression Results
[0042] ① Expression level verification: Recombinant protein was detected by 12% SDS-PAGE electrophoresis, and the staining results are as follows. Figure 2 As shown, different signal peptides lead to differences in protein expression levels. Protein separation gels were transferred to PVDF membranes of the same size using a wet transfer method at 70V for 100 min. After transfer, the membrane was washed with TBST, removed, blocked with 5% skim milk powder for 1 hour, and then washed with TBST. The membrane was placed in a hybridization bag, and 2 mL of diluted (1:1000) primary antibody was added. After heat sealing, the membrane was incubated overnight at 4℃. The next day, the hybridization bag was cut open, the membrane was placed on a petri dish, and washed repeatedly 2-3 times. 4 mL of diluted (1:1000) secondary antibody (goat anti-chicken IgG-HRP) was added, and the mixture was reacted on a shaker for 2 hours. The secondary antibody was discarded, and the membrane was washed with TBS-T. A chemiluminescent substrate was added to the front of the PVDF membrane in the dark, and the membrane was exposed using a Bio-rad chemiluminescence imaging system. Western blot results showed (…). Figure 3 The codon-optimized sequences of CHO cells were introduced with different signal peptides and then linked to the pEE12.4 vector. The expression supernatant containing the SP1, SP2 and SP3 signal peptide sequences could specifically bind to the antibody and showed a relatively obvious reaction band at 50KD, indicating that the exogenous protein could be well expressed in CHO cells.
[0043] ②Valence verification
[0044] To determine the feasibility of using antigen proteins as raw materials for vaccine production, researchers often use standard positive serum of the bursa of Fabricius to detect the agar amplification titer of bursa of Fabricius proteins. We performed 2, 4, 8, 16, 32, 64, 128, and 256-fold dilutions on different culture supernatants, and used a two-way agar diffusion assay to determine the maximum dilution factor at which precipitation lines appeared between the culture supernatant and the positive antibody. This was defined as the agar amplification titer of the culture supernatant. The results are shown in Table 2. The sequencer with SP1 introduced showed the highest agar amplification titer, reaching up to 64. Using this signal peptide plasmid, three stable CHO cell lines were constructed and screened, with the highest agar amplification titer of 128 in the cell line culture supernatant, demonstrating that the obtained stable cell lines can yield a large amount of the target protein at a high titer.
[0045] Table 2. Results of titer assays for different VP2 proteins
[0046]
[0047] Example 2: Vaccine Efficacy Evaluation
[0048] One hundred and forty 21-day-old SPF chickens were randomly divided into seven groups of 20 each. Groups 1 to 3 used CHO cell-expressed bursal disease protein prepared in Example 2, diluted with agar at concentrations of 1:8, 1:16, and 1:32, respectively, and formulated with Marcol-52 white oil as adjuvant. Group 4 used E. coli-expressed bursal disease protein vaccine with a protein titer of 1:16, also using Marcol-52 white oil as adjuvant. Group 5 used a commercially available vaccine. Group 6 was a challenge control group, and Group 7 was a blank control group. Except for the blank and challenge control groups, all chickens in groups 1-5 were immunized via subcutaneous injection in the neck, with each chicken receiving 0.2 mL. Twenty-one days post-immunization, groups 1-6 were challenged with the virulent HuN strain and the FJ variant strain of bursal disease, respectively. FJ variant challenge information and evaluation criteria: oral administration of the IBDV FJ strain yielded a viral load of 10 BID / 0.2 mL. Following viral challenge, chickens were observed for four consecutive days, and morbidity and mortality were recorded. Four days after challenge, all chickens were dissected to observe bursal disease lesions. Infection was defined as any of the following: swollen, atrophied, or yellowed bursa of Fabricius containing gelatinous secretions. Information and evaluation criteria for HuN virulent strain challenge: Oral dose 100 CLD50; morbidity was observed after challenge; bursal damage was observed on day 5 post-challenge after dissection.
[0049] The results are shown in the table below. The vaccine group with a CHO cell-expressed protein titer of 1:8 showed the same protection rate against the FJ variant of infectious bursal disease as the commercial vaccine. Vaccines with a titer of 1:16 or higher achieved 100% immunoprotection against both the variant and the virulent strain. The vaccine group expressing E. coli showed only 70% protection against the variant. All chickens in the challenge control group developed the disease after challenge, while all chickens in the blank control group remained normal.
[0050]
[0051] This invention uses the CHO expression system to induce the expression of the recombinant chicken infectious bursal disease VP2 gene and formulates it into a vaccine. Animal experiments have verified that this vaccine has an ideal protective effect against chicken infectious bursal disease. This provides a good foundation for further research on chicken infectious bursal disease subunit vaccines.
[0052] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A recombinant chicken bursal disease virus VP2 gene expression system, characterized in that: The expression system comprises a recombinant chicken bursal disease virus VP2 gene, a signal peptide and an expression cassette composed of a vector; the nucleotide sequence of the recombinant chicken bursal disease virus VP2 gene is shown in SEQ ID NO.
1.
2. The recombinant chicken bursal disease virus VP2 gene expression system according to claim 1, characterized in that: The recombinant chicken bursal disease virus VP2 gene expression system is constructed by mammalian cell CHO.
3. The recombinant chicken bursal disease virus VP2 gene expression system according to claim 1, characterized in that: The signal peptide is any one of Human IL-2, Human OSM, and Mouse Igκ.
4. The recombinant chicken bursal disease virus VP2 gene expression system according to claim 1, characterized in that: The vector is a pEE12.4 vector, which is connected after being double-digested with HindⅢ and EcoRI.
5. The expression system of the recombinant chicken bursal disease virus VP2 gene according to claim 1, characterized in that: The method for constructing a recombinant chicken bursal virus VP2 gene expression system comprises: 1) connecting the N-terminus of the recombinant chicken bursal disease virus VP2 gene sequence to the signal peptide; 2) pEE12.4 vector was double-digested with HindⅢ and EcoRI and then connected with the product in 1); 3) transforming the ligation product of 2) into DH5α and extracting the plasmid; 4) Use CHO cells to express the plasmid in 3).
6. Use of the method for constructing the expression system of the recombinant chicken bursal disease virus VP2 gene as claimed in claim 5 in the preparation of chicken bursal disease virus vaccine.
